Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:25:29.309Z.
Calculation as of: 2026-10-06T14:25:29.309Z.
Quote observation: 2026-10-06T14:25:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-05-08.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$342.23M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.67M
EV/Sales Ratio
30.01x
TTM Avg
114.38x
3Y Avg
98.11x
5Y Avg
98.11x
Market Cap
$352.03M
EV/Sales Ratio
5.74x
TTM Avg
7.29x
3Y Avg
5.92x
5Y Avg
7.97x
Market Cap
$354.49M
EV/Sales Ratio
5.29x
TTM Avg
5.77x
3Y Avg
8.21x
5Y Avg
104.30x
Market Cap
$333.48M
EV/Sales Ratio
8.71x
TTM Avg
11.65x
3Y Avg
9.91x
5Y Avg
10.67x
Market Cap
$322.30M
EV/Sales Ratio
8.58x
TTM Avg
9.26x
3Y Avg
9.89x
5Y Avg
12.44x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $342.23M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $338.34M | 2.72x | 2.61x | 2.26x | 2.97x |
| Opus Genetics, Inc. (IRD)vs › | $349.67M | 30.01x | 114.38x | 98.11x | 98.11x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.03M | 5.74x | 7.29x | 5.92x | 7.97x |
| Embecta Corp. (EMBC)vs › | $352.12M | 1.61x | 1.60x | 1.83x | 2.04x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.49M | 5.29x | 5.77x | 8.21x | 104.30x |
| ClearPoint Neuro, Inc. (CLPT)vs › | $333.48M | 8.71x | 11.65x | 9.91x | 10.67x |
| C4 Therapeutics, Inc. (CCCC)vs › | $322.30M | 8.58x | 9.26x | 9.89x | 12.44x |
| Cabaletta Bio, Inc. (CABA)vs › | $321.22M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $319.77M | 22.42x | 22.11x | 20.81x | 20.81x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2025-05-08 | 108.49x |
| 2025-05-07 | 100.72x |
| 2025-05-06 | 83.25x |
| 2025-05-05 | 111.40x |
| 2025-05-02 | 133.73x |
| 2025-05-01 | 126.93x |
| 2025-04-30 | 128.87x |
| 2025-04-29 | 134.70x |
| 2025-04-28 | 134.70x |
| 2025-04-25 | 136.64x |
| 2025-04-24 | 134.70x |
| 2025-04-23 | 134.70x |
| 2025-04-22 | 134.70x |
| 2025-04-21 | 129.84x |
| 2025-04-17 | 114.31x |
| 2025-04-16 | 120.14x |
| 2025-04-15 | 124.99x |
| 2025-04-14 | 87.13x |
| 2025-04-11 | 89.08x |
| 2025-04-10 | 75.49x |
| 2025-04-09 | 90.05x |
| 2025-04-08 | 83.25x |
| 2025-04-07 | 218.17x |
| 2025-04-04 | 133.73x |
| 2025-04-03 | 143.43x |
| 2025-04-02 | 174.49x |
| 2025-04-01 | 188.08x |
| 2025-03-31 | 188.08x |
| 2025-03-28 | 203.61x |
| 2025-03-27 | 240.50x |
| 2025-03-26 | 250.20x |
| 2025-03-25 | 284.17x |
| 2025-03-24 | 20.78x |
| 2025-03-21 | 24.14x |
| 2025-03-20 | 21.99x |
| 2025-03-19 | 25.73x |
| 2025-03-18 | 31.52x |
| 2025-03-17 | 39.08x |
| 2025-03-14 | 31.89x |
| 2025-03-13 | 36.56x |
| 2025-03-12 | 42.63x |
| 2025-03-11 | 39.36x |
| 2025-03-10 | 33.85x |
| 2025-03-07 | 34.32x |
| 2025-03-06 | 31.89x |
| 2025-03-05 | 26.20x |
| 2025-03-04 | 25.26x |
| 2025-03-03 | 20.87x |
| 2025-02-28 | 23.02x |
| 2025-02-27 | 19.10x |
| 2025-02-26 | 20.31x |
| 2025-02-25 | 19.38x |
| 2025-02-24 | 19.47x |
| 2025-02-21 | 19.47x |
| 2025-02-20 | 19.66x |
| 2025-02-19 | 21.81x |
| 2025-02-18 | 22.55x |
| 2025-02-14 | 25.73x |
| 2025-02-13 | 21.71x |
| 2025-02-12 | 18.63x |
| 2025-02-11 | 19.01x |
| 2025-02-10 | 21.99x |
| 2025-02-07 | 20.78x |
| 2025-02-06 | 27.22x |
| 2025-02-05 | 29.84x |
| 2025-02-04 | 29.18x |
| 2025-02-03 | 29.93x |
| 2025-01-31 | 31.71x |
| 2025-01-30 | 34.69x |
| 2025-01-29 | 34.51x |
| 2025-01-28 | 36.19x |
| 2025-01-27 | 39.83x |
| 2025-01-24 | 39.64x |
| 2025-01-23 | 42.63x |
| 2025-01-22 | 45.43x |
| 2025-01-21 | 50.29x |
| 2025-01-17 | 45.24x |
| 2025-01-16 | 47.58x |
| 2025-01-15 | 50.75x |
| 2025-01-14 | 49.35x |
| 2025-01-13 | 55.80x |
| 2025-01-10 | 71.58x |
| 2025-01-08 | 80.07x |
| 2025-01-07 | 83.06x |
| 2025-01-06 | 83.25x |
| 2025-01-03 | 83.90x |
| 2025-01-02 | 77.37x |
| 2024-12-31 | 78.39x |
| 2024-12-30 | 83.06x |
| 2024-12-27 | 83.62x |
| 2024-12-26 | 82.60x |
| 2024-12-24 | 86.61x |
| 2024-12-23 | 82.13x |
| 2024-12-20 | 88.01x |
| 2024-12-19 | 77.65x |
| 2024-12-18 | 77.37x |
| 2024-12-17 | 87.36x |
| 2024-12-16 | 81.38x |
| 2024-12-13 | 83.44x |
| 2024-12-12 | 84.00x |
| 2024-12-11 | 92.96x |
| 2024-12-10 | 99.03x |
| 2024-12-09 | 94.17x |
| 2024-12-06 | 94.45x |
| 2024-12-05 | 92.59x |
| 2024-12-04 | 103.04x |
| 2024-12-03 | 102.02x |
| 2024-12-02 | 103.32x |
| 2024-11-29 | 103.61x |
| 2024-11-27 | 101.92x |
| 2024-11-26 | 98.28x |
| 2024-11-25 | 94.55x |
| 2024-11-22 | 88.85x |
| 2024-11-21 | 85.82x |
| 2024-11-20 | 86.61x |
| 2024-11-19 | 89.79x |
| 2024-11-18 | 80.54x |
| 2024-11-15 | 78.21x |
| 2024-11-14 | 82.41x |
| 2024-11-13 | 93.52x |
| 2024-11-12 | 9.77x |
| 2024-11-11 | 10.02x |
| 2024-11-08 | 9.80x |
| 2024-11-07 | 10.48x |
| 2024-11-06 | 10.88x |
| 2024-11-05 | 8.84x |
| 2024-11-04 | 8.27x |
| 2024-11-01 | 7.90x |
| 2024-10-31 | 7.44x |
| 2024-10-30 | 7.45x |
| 2024-10-29 | 8.01x |
| 2024-10-28 | 7.80x |
| 2024-10-25 | 7.69x |
| 2024-10-24 | 7.45x |
| 2024-10-23 | 8.08x |
| 2024-10-22 | 8.36x |
| 2024-10-21 | 7.71x |
| 2024-10-18 | 9.05x |
| 2024-10-17 | 9.54x |
| 2024-10-16 | 10.19x |
| 2024-10-15 | 9.37x |
| 2024-10-14 | 10.74x |
| 2024-10-11 | 11.38x |
| 2024-10-10 | 10.63x |
| 2024-10-09 | 11.16x |
| 2024-10-08 | 11.19x |
| 2024-10-07 | 10.91x |
| 2024-10-04 | 11.97x |
| 2024-10-03 | 11.62x |
| 2024-10-02 | 11.88x |
| 2024-10-01 | 11.64x |
| 2024-09-30 | 11.66x |
| 2024-09-27 | 10.52x |
| 2024-09-26 | 9.97x |
| 2024-09-25 | 11.39x |
| 2024-09-24 | 9.57x |
| 2024-09-23 | 9.36x |
| 2024-09-20 | 9.28x |
| 2024-09-19 | 8.70x |
| 2024-09-18 | 8.84x |
| 2024-09-17 | 8.08x |
| 2024-09-16 | 7.17x |
| 2024-09-13 | 7.29x |
| 2024-09-12 | 7.91x |
| 2024-09-11 | 8.54x |
| 2024-09-10 | 8.75x |
| 2024-09-09 | 8.92x |
| 2024-09-06 | 8.93x |
| 2024-09-05 | 8.85x |
| 2024-09-04 | 8.42x |
| 2024-09-03 | 8.13x |
| 2024-08-30 | 8.55x |
| 2024-08-29 | 5.09x |
| 2024-08-28 | 4.89x |
| 2024-08-27 | 4.76x |
| 2024-08-26 | 4.81x |
| 2024-08-23 | 4.39x |
| 2024-08-22 | 4.38x |
| 2024-08-21 | 4.43x |
| 2024-08-20 | 4.44x |
| 2024-08-19 | 4.62x |
| 2024-08-16 | 5.31x |
| 2024-08-15 | 5.12x |
| 2024-08-14 | 5.16x |
| 2024-08-13 | 5.04x |
| 2024-08-12 | 5.05x |
| 2024-08-09 | 5.09x |
| 2024-08-08 | 4.93x |
| 2024-08-07 | 5.09x |
| 2024-08-06 | 4.98x |
| 2024-08-05 | 4.98x |
| 2024-08-02 | 5.30x |
| 2024-08-01 | 5.25x |
| 2024-07-31 | 5.36x |
| 2024-07-30 | 5.29x |
| 2024-07-29 | 5.41x |
| 2024-07-26 | 5.47x |
| 2024-07-25 | 5.42x |
| 2024-07-24 | 5.36x |
| 2024-07-23 | 5.47x |
| 2024-07-22 | 5.34x |
| 2024-07-19 | 5.47x |
